4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
First Tracks Biotherapeutics, Inc. (TRAX) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 104 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2024-12-31, TRAX reported $0M in revenue and ($164M) in net income.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.
Interactive charts & full statements →
| Income statement | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($181M) | ($118M) |
| Net Income | ($164M) | ($106M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($53M) | ($51M) |
| Net Income | ($50M) | ($47M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Total Assets | $442M | $444M |
| Total Liabilities | $50M | $34M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TRAX viewer.
About TickerBase · Data methodology & sources